Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group

• Published in: Thrombosis research Vol. 233; pp. 153 - 164
• Main Authors: Frenzel, Laurent, Decaux, Olivier, Macro, Margaret, Belhadj-Merzoug, Karim, Manier, Salomon, Touzeau, Cyrille, Leleu, Xavier, Frère, Corinne, Lecompte, Thomas, Perrot, Aurore, Avet-Loiseau, Hervé, Moreau, Philippe, Chalayer, Emilie
• Format: Journal Article
• Language: English
• Published: United States Elsevier 01.01.2024
• Series: Thrombosis Research
• Subjects: Cancer; Cardiology and cardiovascular system; Hematology; Human health and pathology; Immunology; Immunotherapy; Life Sciences; Pharmaceutical sciences; Pharmacology; Santé publique et épidémiologie; Immunomodulatory drugs; Direct oral anticoagulants; Venous thromboembolism; Multiple myeloma; Prophylaxis
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2023.11.021

Venous thromboembolism (VTE) remains a critical issue in the management of patients with multiple myeloma (MM), particularly when immunomodulatory drugs (IMiDs) combined with dexamethasone therapy are being prescribed as first-line and relapse therapy. One possible explanation for the persistent high rates of VTE, is the use of inappropriate thromboprophylaxis strategies for patients starting antimyeloma treatment. To tackle the issue, the Intergroupe francophone du myélome (IFM) offered convenient guidance for VTE thromboprophylaxis in MM patients initiating systemic therapy. This guidance is mainly supported by the results of a large survey on the clinical habits regarding VTE of physicians who are substantially involved in daily care of MM patients. VTE prophylaxis should be considered for all patients treated with IMiDs in combination with dexamethasone, in the absence of significant comorbidities, such as renal failure or bleeding risk. Anticoagulant should be preferred to antiplatelet agents for thromboprophylaxis. Despite the absence of large randomized controlled trials comparing those attitudes/options, available data on direct oral anticoagulants, which are already used in daily management of MM patients, are consistent with their potential usefulness for VTE prophylaxis in such patients. However, in order to implement a personalized continuous improvement strategy, clinicians must to be organized to collect all the data regarding this management. In other situations, thromboprophylaxis should be evaluated by using risk models and after careful evaluation of the risk/benefit ratio.